



www.MedChemExpress.com











Inhibitors, Screening Libraries, Proteins











Sigma Receptor

Sigma receptors (subtypes sigma-1 and sigma-2) are a unique class of binding sites expressed throughout the mammalian body. The endogenous ligand for these sites has not been identified, but steroid hormones (particularly progesterone), sphingolipid-derived amines and N,N-dimethyltryptamine can bind with fairly high affinity.

The sigma-1 receptor ($\sigma 1R$) is an endoplasmic reticulum (ER)-resident chaperone protein that acts like an inter-organelle signaling modulator. It participates in many biological processes including nociception, cancer, stroke, memory, drug addiction, cardiac activity, and Alzheimer's disease. The sigma-2 ($\sigma 2R$) receptor is overexpressed in various human tumors. It has been validated as a biomarker for proliferating tumors.

Sigma Receptor Agonists, Antagonists, Modulators & Inhibitors


<p>(2R,3R)-E1R</p> <p>Cat. No.: HY-116463C</p> <p>(2R,3R)-E1R (Compound 2b) is an enantiomer of E1R. (2R,3R)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.</p>  <p>Purity: 98.79% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>	<p>(2R,3S)-E1R</p> <p>Cat. No.: HY-116463A</p> <p>(2R,3S)-E1R (Compound 2c) is an enantiomer of E1R. (2R,3S)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.</p>  <p>Purity: 98.84% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>
<p>(2S,3S)-E1R</p> <p>Cat. No.: HY-116463B</p> <p>(2S,3S)-E1R (Compound 2d) is an enantiomer of E1R. (2S,3S)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.</p>  <p>Purity: 98.24% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>	<p>(Rac)-E1R</p> <p>Cat. No.: HY-116463D</p> <p>(Rac)-E1R (Compound 2) is the racemate of E1R. (Rac)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) used for the research of cognition/memory disorders.</p>  <p>Purity: 98.48% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg</p>
<p>(±)-Vesamicol hydrochloride ((±)-AH5183 hydrochloride)</p> <p>Cat. No.: HY-B1813A</p> <p>(±)-Vesamicol hydrochloride ((±)-AH5183 hydrochloride) is a potent vesicular acetylcholine transport inhibitor with a K_i of 2 nM. (±)-Vesamicol hydrochloride also displays high affinity for σ_1 and σ_2 receptors with K_is of 26 nM and 34 nM, respectively.</p>  <p>Purity: 99.72% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg</p>	<p>4-IBP</p> <p>Cat. No.: HY-100155</p> <p>4-IBP is a selective σ_1 agonist with a high level of affinity for the σ_1 receptor ($K_i = 1.7$ nM) and a moderate affinity for the σ_2 receptor ($K_i = 25.2$ nM).</p>  <p>Purity: 99.81% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>4-PPBP maleate</p> <p>Cat. No.: HY-101043</p> <p>4-PPBP maleate is a potent σ_1 receptor ligand and agonist. 4-PPBP maleate is a non-competitive, selective NR1a/2B NMDA receptors (expressed in Xenopus oocytes) antagonist. 4-PPBP maleate provides neuroprotection.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>BD-1047 dihydrobromide</p> <p>Cat. No.: HY-16996A</p> <p>BD-1047 (dihydrobromide) is a selective functional antagonist of sigma-1 receptor, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.</p>  <p>Purity: 99.78% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>
<p>BD1063 dhydrochloride</p> <p>Cat. No.: HY-18101A</p> <p>BD1063 dhydrochloride is a potent and selective sigma 1 receptor antagonist.</p>  <p>Purity: 96.77% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>Blarcomesine</p> <p>Cat. No.: HY-105296</p> <p>Blarcomesine is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcomesine ameliorates neurologic impairments in a mouse model of Rett syndrome.</p>  <p>Purity: >98% Clinical Data: Phase 2 Size: 1 mg, 5 mg</p>

<p>Blarcomesine hydrochloride</p> <p>Cat. No.: HY-101864</p> <p>Blarcomesine hydrochloride is a Sigma-1 Receptor agonist with an IC_{50} of 860 nM.</p>  <p>H-Cl</p> <p>Purity: 99.85% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Blonanserin (AD-5423)</p> <p>Cat. No.: HY-13575</p> <p>Blonanserin (AD-5423) is a potent and orally active 5-HT_{2A} ($K_i=0.812$ nM) and dopamine D2 receptor ($K_i=0.142$ nM) antagonist.</p>  <p>Purity: 98.73% Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 25 mg, 100 mg</p>
<p>BMY-14802 hydrochloride (BMY-14802-1; BMS 181100 hydrochloride)</p> <p>Cat. No.: HY-108509</p> <p>BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally active sigma receptor antagonist with an IC_{50} of 112 nM. BMY-14802 hydrochloride is also a 5-HT1A and adrenergic α1 receptors agonist. BMY-14802 hydrochloride has antipsychotic effects.</p>  <p>H-Cl</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CM398</p> <p>Cat. No.: HY-145628</p> <p>CM398 is a highly selective, orally active sigma-2 receptor ligand ($K_i=0.43$ nM), with high sigma-1/sigma-2 selectivity ratio (1000-fold). CM398 shows notable affinity for dopamine ($K_i=32.90$ nM) and serotonin transporters ($K_i=244.2$ nM).</p>  <p>Purity: 98.09% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>Cutamesine (SA4503; AGY 94806)</p> <p>Cat. No.: HY-14813</p> <p>Cutamesine (SA4503; AGY-94806) is a selective sigma 1 receptor ($\sigma 1R$) agonist; high affinity for the sigma 1 receptor subtype labeled by (+)-[3H]pentazocine ($IC_{50}=17.4\pm 1.9$ nM); 100-fold less affinity for the sigma 2 receptor.</p>  <p>Purity: >98% Clinical Data: Phase 2 Size: 1 mg, 5 mg</p>	<p>Cutamesine dihydrochloride (SA4503 dihydrochloride; AGY94806 dihydrochloride)</p> <p>Cat. No.: HY-13510</p> <p>Cutamesine dihydrochloride (SA4503 dihydrochloride; AGY94806 dihydrochloride) is a potent Sigma 1 receptor agonist with an IC_{50} of 17.4 nM in guinea pig brain membranes.</p>  <p>HCl HCl</p> <p>Purity: 99.48% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 10 mg, 50 mg</p>
<p>Dimemorfan phosphate</p> <p>Cat. No.: HY-B2215</p> <p>Dimemorfan phosphate is a sigma 1 receptor agonist, used as a potent antitussive.</p>  <p>Purity: 99.97% Clinical Data: Launched Size: 10 mM × 1 mL, 50 mg, 100 mg</p>	<p>Ditolyguanidine (1,3-Di-o-tolylguanidine; DTG)</p> <p>Cat. No.: HY-14218</p> <p>Ditolyguanidine (1,3-Di-o-tolylguanidine) is an agonist of sigma receptor ($\sigma 1/\sigma 2$ receptor).</p>  <p>Purity: 99.03% Clinical Data: Phase 4 Size: 10 mM × 1 mL, 500 mg, 1 g</p>
<p>DuP 734</p> <p>Cat. No.: HY-136281</p> <p>DuP 734 is a sigma receptor antagonist. DuP 734 is a selective and potent sigma and 5-HT₂ receptor ligand with weak affinity for D₂ receptors. DuP 734 may have antipsychotic activity without the liability of motor side effects typical of neuroleptics.</p>  <p>H-Br</p> <p>Purity: 98.27% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>E1R</p> <p>Cat. No.: HY-116463</p> <p>E1R is a positive allosteric modulator of sigma-1 receptors (Sig1R PAM) with cognition-enhancing activity.</p>  <p>Purity: 99.28% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>

EST64454 hydrochloride

Cat. No.: HY-131914A

EST64454 hydrochloride is a selective and orally active **sigma-1 receptor** antagonist with a K_i of 22 nM. EST64454 hydrochloride has the potential for the research of the pain.




Purity: 99.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EST73502

Cat. No.: HY-134189

EST73502 is a selective, orally active and blood-brain barrier (BBB) penetrant dual **mu-opioid receptor (MOR)** agonist and **sigma-1 receptor (sigma-1R)** antagonist, with K_s of 64 nM and 118 nM for MOR and sigma-1R, respectively. EST73502 has antinociceptive activity.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EST73502 hydrochloride

Cat. No.: HY-134189A

EST73502 hydrochloride is a selective, orally active and blood-brain barrier (BBB) penetrant dual **mu-opioid receptor (MOR)** agonist and **sigma-1 receptor (sigma-1R)** antagonist, with K_s of 64 nM and 118 nM for MOR and sigma-1R, respectively. EST73502 hydrochloride has antinociceptive activity.




Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Glycerol phenylbutyrate

(HPN-100)

Cat. No.: HY-B2087

Glycerol phenylbutyrate is a **sigma-2 (sigma-2)** receptor ligand, with a pK_i of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.




Purity: 99.81%
Clinical Data: Launched
Size: 10 mM x 1 mL, 10 mg, 50 mg, 100 mg

Glycerol phenylbutyrate-D15

(HPN-100-D15)

Cat. No.: HY-B2087S

Glycerol phenylbutyrate-D15 is a deuterium labeled Glycerol phenylbutyrate. Glycerol phenylbutyrate is a **sigma-2 (sigma-2)** receptor ligand, with a pK_i of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glycerol phenylbutyrate-D5

(HPN-100-D5)

Cat. No.: HY-B2087S1

Glycerol phenylbutyrate-D5 is a deuterium labeled Glycerol phenylbutyrate. Glycerol phenylbutyrate is a **sigma-2 (sigma-2)** receptor ligand, with a pK_i of 8.02. Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IPAG

Cat. No.: HY-100985

IPAG is a potent **sigma-1 receptor** antagonist with a pK_i of 4.3. IPAG induces **apoptosis**.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KB-5492 anhydrous

Cat. No.: HY-19120

KB-5492 anhydrous is a potent and selective inhibitor of **sigma receptor**, inhibits specific [3 H]1,3-di-(2-tolyl)guanidine (DTG) binding to the **sigma receptor** with an IC_{50} of 3.15 μ M. KB-5492 anhydrous is an anti-ulcer agent.




Purity: 99.50%
Clinical Data: No Development Reported
Size: 5 mg

OPC-14523 free base

Cat. No.: HY-116594

OPC-14523 free base is an orally active **sigma** and **5-HT1A receptor** agonist, with high affinity for sigma receptors ($\sigma_1/2$ IC_{50} =47/56 nM), the 5-HT1A receptor (IC_{50} =2.3 nM), and the 5-HT transporter (IC_{50} =80 nM). OPC-14523 free base shows antidepressant-like activity.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg











OPC-14523 hydrochloride

Cat. No.: HY-116594A

OPC-14523 hydrochloride is an orally active **sigma** and **5-HT1A receptor** agonist, with high affinity for sigma receptors ($\sigma_1/2$ IC_{50} =47/56 nM), the 5-HT1A receptor (IC_{50} =2.3 nM), and the 5-HT transporter (IC_{50} =80 nM). OPC-14523 hydrochloride shows antidepressant-like activity.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg


<p>Panamesine (EMD 57445)</p> <p>Panamesine (EMD 57445) is a sigma receptor ligand, which has a high affinity (IC_{50} 6 nM) and selectivity for sigma binding sites. Panamesine is a potential atypical neuroleptic agent.</p> <p>Purity: 99.74% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>  <p>Cat. No.: HY-136280</p>	<p>PB28</p> <p>PB28 is a cyclohexylpiperazine derivative and a high affinity and selective sigma 2 (σ2) receptor agonist with a K_i of 0.68 nM. PB28 is also a σ1 antagonist with a K_i of 0.38 nM. PB28 is less affinity for other receptors.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>  <p>Cat. No.: HY-108511A</p>
<p>PB28 dihydrochloride</p> <p>PB28 dihydrochloride, a cyclohexylpiperazine derivative, is a high affinity and selective sigma 2 (σ2) receptor agonist with a K_i of 0.68 nM. PB28 dihydrochloride is also a σ1 antagonist with a K_i of 0.38 nM.</p> <p>Purity: 99.53% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>  <p>Cat. No.: HY-108511</p>	<p>PD 144418</p> <p>PD 144418 is a highly affinity, potent and selective sigma 1 (σ1) receptor ligand (K_i values of 0.08 nM and 1377 nM for σ1 and σ2 respectively). PD 144418 devoids of any significant affinity for other receptors, ion channels and enzymes.</p> <p>Purity: 98.32% Clinical Data: No Development Reported Size: 2 mg</p>  <p>Cat. No.: HY-108512</p>
<p>PD 144418 oxalate</p> <p>PD 144418 oxalate is a highly affinity, potent and selective sigma 1 (σ1) receptor ligand (K_i values of 0.08 nM and 1377 nM for σ1 and σ2 respectively). PD 144418 oxalate devoids of any significant affinity for other receptors, ion channels and enzymes.</p> <p>Purity: ≥98.0% Clinical Data: No Development Reported Size: 2 mg</p>  <p>Cat. No.: HY-108512A</p>	<p>Pentoxiverine (Carbetapentane)</p> <p>Pentoxiverine (Carbetapentane) is a sigma-1 receptor agonist, with a K_i of 75 nM on guinea-pig brain membranes. Pentoxiverine is a centrally-acting cough suppressant with antimuscarinic and anticonvulsant properties.</p> <p>Purity: 98.37% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg</p>  <p>Cat. No.: HY-134004</p>
<p>Pentoxiverine-d8</p> <p>Pentoxiverine-d8 (Carbetapentane-d8) is the deuterium labeled Pentoxiverine. Pentoxiverine (Carbetapentane) is a sigma-1 receptor agonist, with a K_i of 75 nM on guinea-pig brain membranes.</p> <p>Purity: >98% Clinical Data: Size: 1 mg, 10 mg</p>  <p>Cat. No.: HY-134004S</p>	<p>PRE-084 hydrochloride</p> <p>PRE-084 hydrochloride is a high affinity, selective σ1 agonist, has an IC_{50} of 44 nM in the sigma receptor assay.</p> <p>Purity: 99.79% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg</p>  <p>Cat. No.: HY-18100A</p>
<p>Rimcazole dihydrochloride (BW 234U dihydrochloride)</p> <p>Rimcazole (BW 234U) dihydrochloride is a carbazole derivative that acts in part as a sigma (σ) receptor antagonist. Rimcazole dihydrochloride also binds with moderate affinity to the dopamine transporter and inhibit dopamine uptake.</p> <p>Purity: 99.80% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>  <p>Cat. No.: HY-108510</p>	<p>Roluperidone (CYR-101; MIN-101; MT-210)</p> <p>Roluperidone (CYR-101) is a novel cyclic amide derivative that has high equipotent affinities for 5-HT_{2A} and sigma-2 receptors (K_i of 7.53 nM and 8.19 nM for 5-HT_{2A} and sigma-2, respectively).</p> <p>Purity: 99.51% Clinical Data: Phase 3 Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</p>  <p>Cat. No.: HY-19469</p>

<p>S1RA (E-52862)</p> <p>S1RA(E-52862) is a potent and selective sigma-1 receptor(σ1R, $K_i=17$ nM) antagonist, showed good selectivity against σ2R ($K_i > 1000$ nM). IC50 value: 17 nM (K_i) Target: σ1R in vitro: S1RA behaved as a highly selective σ1 receptor antagonist.</p> <p>Purity: $\geq 98.0\%$ Clinical Data: Phase 2 Size: 5 mg, 10 mg</p>	<p>S1RA hydrochloride (E-52862 hydrochloride)</p> <p>S1RA hydrochloride (E-52862 hydrochloride) is a potent and selective sigma-1 receptor(σ1R, $K_i=17$ nM) antagonist, showed good selectivity against σ2R ($K_i > 1000$ nM). IC50 value: 17 nM (K_i) Target: σ1R antagonist in vitro: S1RA behaved as a highly selective σ1 receptor antagonist.</p> <p>Purity: 99.85% Clinical Data: Phase 2 Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 250 mg</p>
<p>Sigma-1 receptor antagonist 1</p> <p>Sigma1 receptor antagonist 1 (compound 137) is a potent and selective sigma-1 receptor (σ1R) antagonist, with a high binding affinity to σ1R receptor ($K_i = 1.06$ nM).</p> <p>Purity: 99.76% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>	<p>Sigma-1 receptor antagonist 2</p> <p>Sigma-1 receptor antagonist 2 is a potent and selective sigma 1 receptor (σ1 R) antagonist with K_s of 3.88 and 1288 nM for σ1 and σ2 receptor, respectively.</p> <p>Purity: 99.14% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>
<p>Sigma-1 receptor antagonist 3</p> <p>Sigma-1 receptor antagonist 3 (compound135) is a potent and selective Sigma-1 (σ1) receptor antagonist with a K_i of 1.14 nM. Sigma-1 receptor antagonist 3 inhibits Human Ether-a-go-go-Related Gene (hERG) with an IC_{50} of 1.54 μM.</p> <p>Purity: 99.47% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>	<p>Sigma-2 receptor antagonist 1</p> <p>Sigma-2 receptor antagonist 1 is a sigma-2 (σ-2) receptor antagonist.</p> <p>Purity: 97.15% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg</p>
<p>Sigma-LIGAND-1</p> <p>Sigma-LIGAND-1 is a selective sigma receptor ligand with an IC_{50}s of 16 nM, 19 nM at the DTG site and the PPP site, respectively. Sigma-LIGAND-1 has a K_i of 4000 nM at the dopamine D_2 receptor.</p> <p>Purity: $>98\%$ Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Sigma-LIGAND-1 hydrochloride</p> <p>Sigma-LIGAND-1 hydrochloride is a selective sigma receptor ligand with an IC_{50}s of 16 nM, 19 nM at the DTG site and the PPP site, respectively. Sigma-LIGAND-1 hydrochloride has a K_i of 4000 nM at the dopamine D_2 receptor.</p> <p>Purity: $>98\%$ Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Siramesine (Lu 28-179)</p> <p>Siramesine (Lu 28-179) is a potent sigma-2 receptor agonist. Siramesine has a subnanomolar affinity for sigma-2 receptors ($IC_{50}=0.12$nM) and exhibits a 140-fold selectivity for sigma-2 receptors over sigma-1 receptors ($IC_{50}=17$nM).</p> <p>Purity: $>98\%$ Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Siramesine hydrochloride (Lu 28-179 hydrochloride)</p> <p>Siramesine (Lu 28-179) hydrochloride is a potent sigma-2 receptor agonist. Siramesine hydrochloride has a subnanomolar affinity for sigma-2 receptors ($IC_{50}=0.12$nM) and exhibits a 140-fold selectivity for sigma-2 receptors over sigma-1 receptors ($IC_{50}=17$nM).</p> <p>Purity: 99.85% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>

SKF 83959 hydrobromide

Cat. No.: HY-103412

SKF83959 hydrobromide is a potent and selective dopamine D₁-like receptor partial agonist. SKF83959 hydrobromide K_i values for rat D₁, D₅, D₂ and D₃ receptors are 1.18, 7.56, 920 and 399 nM, respectively.




Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg

SKF83959

Cat. No.: HY-130344

SKF83959 is a potent and selective dopamine D₁-like receptor partial agonist. SKF83959 K_i values for rat D₁, D₅, D₂ and D₃ receptors are 1.18, 7.56, 920 and 399 nM, respectively. SKF83959 is a potent allosteric modulator of sigma (σ)-1 receptor.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR-31747

Cat. No.: HY-13751

SR-31747 is a sigma ligand with immunosuppressive and anti-inflammatory properties. SR-31747 blocks cell proliferation by inhibiting sterol isomerase.




Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SR-31747 free base

Cat. No.: HY-13751A

SR-31747 free base is a sigma ligand with immunosuppressive and anti-inflammatory properties. SR-31747 blocks cell proliferation by inhibiting sterol isomerase.




Purity: 95.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

σ1 Receptor antagonist-1

Cat. No.: HY-10815

σ1 Receptor antagonist-1 is a highly potent and selective sigma 1 receptor antagonist (pK_i=10.28). σ1 Receptor antagonist-1 inhibits cell growth, arrests cell cycle at G₀/G₁ phase and induces apoptosis of MCF-7/ADR cells.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg